Inactive Instrument

Hutchison China MediTech Limited London S.E.

KYG4672N1198

Hutchison China MediTech : Form-20F Publication

March 03, 2020 at 09:24 am EST

RNS Reach Story

Go to market news section

Hutchison China Meditech Limited - HCM

Form-20F Publication

Released 14:18 03-Mar-2020

RNS Number : 8821E

Hutchison China Meditech Limited

03 March 2020

Press release

Publication of Form 20-F

London: Tuesday, March 3, 2020: Hutchison China MediTech Limited ('Chi-Med') (NasdaqAIM: HCM) today published the Form 20-F for the financial year ended December 31, 2019. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/8821E_1-2020-3-3.pdfand also on the website of the Company at www.chi-med.com.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit:www.chi-med.com.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson	+44 7967 566 919 (Mobile)david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout	+1 (415) 971 9412 (Mobile) xyang@troutgroup.com

Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson	+44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Americas- Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com
Asia	- Joseph Chi Lo, Brunswick	+852 9850 5033 (Mobile) jlo@brunswickgroup.com
	- Zhou Yi, Brunswick	+852 9783 6894(Mobile) yzhou@brunswickgroup.com

Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAJJMITMTMMBIM

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

Form-20F Publication - RNS

Attachments

Original document
Permalink

Disclaimer

Hutchison China Meditech Limited published this content on 03 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2020 14:23:01 UTC

Latest news about Hutchison China MediTech Limited

Hutchmed to Present New Data at US Cancer Research Conference	Apr. 05	MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	Apr. 05	CI
Hutchmed endometrial cancer treatment application accepted for review	Apr. 02	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	Apr. 02	MT
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02	AN
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	Mar. 28	MT
Hutchmed lung cancer treatment accepted for review in China	Mar. 28	AN
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	Mar. 28	MT
JD Sports backs outlook; Spirent accepts new offer	Mar. 28	AN
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	Mar. 28	MT
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	Mar. 27	CI
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	Mar. 22	AN
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	Mar. 22	MT
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	Mar. 22	MT
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	Mar. 21	CI
Hutchmed Returns to Profit in 2023; EPS Tops Estimate	Feb. 29	MT
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN
Hutchmed Swings to 2023 Profit as Revenue Increases	Feb. 28	MT
Hutchmed (China) Swings to Profit in FY23; Revenue Soars	Feb. 28	MT
Transcript : HUTCHMED Limited, 2023 Earnings Call, Feb 28, 2024	Feb. 28
HUTCHMED Limited Provides Revenue Guidance for the Year 2024	Feb. 28	CI
HUTCHMED Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Hutchmed hails fruquintinib trial results for gastric cancer treatment	Feb. 07	AN
Hutchmed Presents Phase 3 Trial Results for Gastric Cancer Drug at US Oncology Meet; Shares Rise 4%	Feb. 07	MT

Chart Hutchison China MediTech Limited

Duration

Period

More charts

Company Profile

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Sector

Pharmaceuticals

Calendar

2024-05-10 - Annual General Meeting

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals